First Real-World Experience Administering Etranacogene Dezaparvovec Gene Therapy for People with Hemophilia B

被引：0
|
作者：
Ryan, Matthew L. [1 ]
Miller, Andrea [2 ]
O'Hearn, Patrick [2 ]
Desai, Vidhi Parikh [3 ]
机构：
[1] Green Bay Oncol, Green Bay, WI USA
[2] Hemophilia Outreach Ctr, Green Bay, WI USA
[3] CSL Behring, King Of Prussia, PA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190238
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
    Pipe, S. W.
    Leebeek, F. W. G.
    Recht, M.
    Key, N. S.
    Castaman, G.
    Miesbach, W.
    Lattimore, S.
    Peerlinck, K.
    Van der Valk, P.
    Coppens, M.
    Kampmann, P.
    Meijer, K.
    O'Connell, N.
    Pasi, K. J.
    Hart, D. P.
    Kazmi, R.
    Astermark, J.
    Hermans, C. R. J. R.
    Klamroth, R.
    Lemons, R.
    Visweshwar, N.
    von Drygalski, A.
    Young, G.
    Crary, S. E.
    Escobar, M.
    Gomez, E.
    Kruse-Jarres, R.
    Quon, D. V.
    Symington, E.
    Wang, M.
    Wheeler, A. P.
    Gut, R.
    Liu, Y. P.
    Dolmetsch, R. E.
    Cooper, D. L.
    Li, Y.
    Goldstein, B.
    Monahan, P. E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (08): : 706 - 718
  • [2] Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec
    Anguela, Xavier M.
    High, Katherine A.
    BLOOD ADVANCES, 2024, 8 (07) : 1796 - 1803
  • [3] Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)
    Sekayan, Tro
    Simmons, Dana H.
    von Drygalski, Annette
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (12) : 1173 - 1184
  • [4] Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
    von Drygalski, Annette
    Gomez, Esteban
    Giermasz, Adam
    Castaman, Giancarlo
    Key, Nigel S.
    Lattimore, Susan U.
    Leebeek, Frank W. G.
    Miesbach, Wolfgang A.
    Recht, Michael
    Gut, Robert
    Dolmetsch, Ricardo
    Monahan, Paul E.
    Le Quellec, Sandra
    Pipe, Steven W.
    BLOOD ADVANCES, 2023, 7 (19) : 5671 - 5679
  • [5] MULTIPLE-YEAR DURABILITY DATA FROM A PHASE 2B TRIAL OF GENE THERAPY WITH ETRANACOGENE DEZAPARVOVEC IN PATIENTS WITH HEMOPHILIA B
    Gomez, E.
    Castaman, G.
    Key, N. S.
    Lattimore, S. U.
    Leebeek, F. W.
    Miesbach, W. A.
    Recht, M.
    von Drygalski, A.
    Cooper, D.
    Li, Y.
    Salazar, B.
    Pipe, S. W.
    HAEMOPHILIA, 2022, 28 : 74 - 75
  • [6] MULTIPLE-YEAR DURABILITY DATA FROM A PHASE 2B TRIAL OF GENE THERAPY WITH ETRANACOGENE DEZAPARVOVEC IN PATIENTS WITH HEMOPHILIA B
    Gomez, Esteban
    Giermasz, Adam
    Castaman, Giancarlo
    Key, Nigel S.
    Lattimore, Susan
    Leebeek, Frank W. G.
    Miesbach, Wolfgang A.
    Recht, Michael
    von Drygalski, Annette
    Cooper, David
    Li, Yanyan
    Salazar, Blanca
    Pipe, Steven W.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E41 - E42
  • [7] EFFICACY AND SAFETY OF ETRANACOGENE DEZAPARVOVEC IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B: FIRST DATA FROM THE PHASE 3 HOPE-B GENE THERAPY TRIAL
    Pipe, S. W.
    Recht, M.
    Key, N. S.
    Leebeek, F. W. G.
    Castaman, G.
    Lattimore, S. U.
    van der Valk, P.
    Peerlinck, K.
    Coppens, M.
    O'Connell, N.
    Pasi, K. J.
    Kampmann, P.
    Meijer, K.
    von Drygalski, A.
    Young, G.
    Hermans, C.
    Astermark, J.
    Klamroth, R.
    Lemons, R. S.
    Visweshwar, N.
    Crary, S.
    Kazmi, R.
    Symington, E.
    Escobar, M. A.
    Gomez, E.
    Kruse-Jarres, R.
    Kotowski, A.
    Quon, D.
    Wang, M.
    Wheeler, A. P.
    Sawyer, E. K.
    Verweij, S.
    Colletta, V.
    Bajwa, N.
    Gut, R.
    Miesbach, W.
    HAEMOPHILIA, 2021, 27 : 65 - 66
  • [8] Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B
    Shah, Jinesh
    Kim, Hongseok
    Sivamurthy, Krupa
    Monahan, Paul E.
    Fries, Michael
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (02) : 227 - 237
  • [9] MANAGEMENT OF DENTAL PROCEDURES AND SURGERIES IN PEOPLE WITH SEVERE AND MODERATELY SEVERE HAEMOPHILIA B WHO WERE TREATED IN GENE THERAPY CLINICAL TRIALS WITH ETRANACOGENE DEZAPARVOVEC
    O'Connell, N.
    Van der Valk, P.
    Gomez, E.
    Monahan, P. E.
    Le Quellec, S.
    Kampmann, P.
    HAEMOPHILIA, 2023, 29 : 18 - 19
  • [10] Response to gene therapy in haemophilia B: Ranges of factor IX sustained after 3 years in HOPE-B etranacogene dezaparvovec gene therapy trial
    Hermans, Cedric
    Coppens, Michiel
    Le Quellec, Sandra
    Galante, Nicholas
    Drelich, Douglass
    Pipe, Steven
    HAEMOPHILIA, 2024, 30 : 25 - 25
12345